Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vanda Pharmaceuticals (VNDA) Common Equity (2016 - 2025)

Vanda Pharmaceuticals (VNDA) has disclosed Common Equity for 17 consecutive years, with $327.2 million as the latest value for Q4 2025.

  • Quarterly Common Equity fell 39.25% to $327.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $327.2 million through Dec 2025, down 39.25% year-over-year, with the annual reading at $327.2 million for FY2025, 39.25% down from the prior year.
  • Common Equity hit $327.2 million in Q4 2025 for Vanda Pharmaceuticals, down from $466.0 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $544.9 million in Q4 2023 to a low of $327.2 million in Q4 2025.
  • Historically, Common Equity has averaged $506.1 million across 5 years, with a median of $513.5 million in 2022.
  • Biggest five-year swings in Common Equity: grew 12.31% in 2021 and later crashed 39.25% in 2025.
  • Year by year, Common Equity stood at $504.9 million in 2021, then rose by 4.41% to $527.2 million in 2022, then increased by 3.36% to $544.9 million in 2023, then dropped by 1.17% to $538.5 million in 2024, then plummeted by 39.25% to $327.2 million in 2025.
  • Business Quant data shows Common Equity for VNDA at $327.2 million in Q4 2025, $466.0 million in Q3 2025, and $486.3 million in Q2 2025.